Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ3PNS)

• Drug Name: P-2745 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic myelogenous leukaemia	2A20.0	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 135565531
  TTD Drug ID: DMJ3PNS

Molecule-Related Drug Atlas

Drug(s) Targeting TGF-beta receptor type I (TGFBR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2157299	DMP8HW1	Arteriosclerosis	BD40	Phase 2/3	[3]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[4]
Metelimumab	DMENFD6	Scleroderma	4A42	Phase 1/2	[5]
TP-0184	DMJVZBC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
LY3200882	DMQP6VB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
PF-06952229	DMDQJEZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
SB-431542	DM0YOXQ	Pulmonary fibrosis	CB03.4	Preclinical	[9]
SM-16	DMHXJV2	Fibrosis	GA14-GC01	Terminated	[10]
LF-984	DMIYMS2	Fibrosis	GA14-GC01	Terminated	[11]
PMID23639540C13d	DMSTQGH	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TGF-beta receptor type I (TGFBR1)	TTP4520	TGFR1_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037259)
• [2] Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822.
• [3] Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
• [6] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.
• [9] Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9.
• [10] TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26.
• [11] US patent application no. 2013,0028,978, Compositions and methods for wound treatment.
• [12] Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.